Combined Effects of **TGFB1** +869 T/C and +915 G/C Polymorphisms on Acute Rejection Risk in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis

Yu-Zheng Ge1,2*, Ran Wu1,2, Tian-Ze Lu1,2, Rui-Peng Jia1,2, Ming-Hao Li1,2, Xiao-Fei Gao3, Xiao-Min Jiang3, Xian-Bo Zhu4, Liang-Peng Li5, Si-Jia Tan1,2, Qun Song1,2, Wen-Cheng Li1,2, Jia-Geng Zhu1,2

1 Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 2 Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 3 Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 4 Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 5 Department of Cardiothoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

**Abstract**

**Background:** Transforming growth factor-beta 1 (TGFB1) is involved in the development of acute rejection (AR) episodes in solid organ transplant recipients; and a number of studies have been conducted to investigate the combined effects of human TGFB1 gene (TGFB1) +869 T/C and +915 G/C polymorphisms on AR risk. However, the results obtained are inconclusive.

**Methods:** Eligible studies that investigated the haplotypic association between **TGFB1** +869 T/C and +915 G/C polymorphisms and AR risk were comprehensively searched in the PUBMED, EMBASE, China National Knowledge Infrastructure, and Wanfang Database. Statistical analyses were performed by using STATA 12.0 and Review Manager 5.0.

**Results:** Fourteen eligible studies with 565 AR cases and 1219 non-AR cases were included. Overall, a significantly decreased risk was detected in patients carried with intermediate producer (IP) haplotypes (T/C G/C, T/T G/C, and T/C C/C) compared with high producer (HP) haplotypes (T/T G/G and T/C G/G; IP vs. HP: OR = 0.75, 95% CI, 0.58–0.96, P heterogeneity = 0.238; IP/HP vs. HP: OR = 0.77, 95% CI, 0.61–0.98, P heterogeneity = 0.144). In addition, subgroup analysis by transplant types demonstrated a similar association in patients receiving heart transplant (IP vs. HP: OR = 0.32, 95% CI, 0.14–0.73, P heterogeneity = 0.790; IP/HP vs. HP: OR = 0.41, 95% CI, 0.20–0.85, P heterogeneity = 0.320).

**Conclusions:** The current meta-analysis and systematic review indicated that recipient **TGFB1** HP haplotypes were significantly associated with an increased risk for AR in solid organ transplant recipients, particularly patients receiving cardiac allograft.

Citation: Ge Y-Z, Wu R, Lu T-Z, Jia R-P, Li M-H, et al. (2014) Combined Effects of **TGFB1** +869 T/C and +915 G/C Polymorphisms on Acute Rejection Risk in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. PLoS ONE 9(4): e93938. doi:10.1371/journal.pone.0093938

Editor: William B. Coleman, University of North Carolina School of Medicine, United States of America

Received January 24, 2014; Accepted March 8, 2014; Published April 4, 2014

Copyright: © 2014 Ge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This project was supported by grants from the National Natural Science Foundation of China (81070597, 81370853), Science and Education Infrastructure, and Wanfang Database. Statistical analyses were performed by using STATA 12.0 and Review Manager 5.0.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: ruipeng_jia@yeah.net

† These authors contributed equally to this work.

**Introduction**

Transforming growth factor-beta 1 (TGFB1) is a multifunctional cytokine ubiquitously produced by a wide variety of cells, including T lymphocytes, monocytes, vascular endothelium, and renal tubular cells [1]. Functionally, TGFB1 has been proven to be of fundamental importance in the development of various disorders [2], including coronary heart disease [3], human cancers [4], rheumatoid arthritis [5], asthma [6] and transplant rejection [7,8]. In the setting of solid organ transplants, TGFB1 has been conventionally recognized as a guardian against acute rejection (AR), as higher level of TGFB1 in the graft tissue and serum was found in non-AR recipients than those suffering AR [9–11]. However, several novel lines of evidence have challenged the beneficial effects of TGFB1 on transplant recipients [12,13]. Although the functional role of TGFB1 in AR initiation remains elusive, this cytokine is believed to exert pivotal and complicated functions in AR episodes.

The human TGFB1 gene (**TGFB1**) is mapped on the chromosome 19q13.1–13.3 with seven exons and six introns, whose regulation and expression is influenced by the presence of
single nucleotide polymorphisms (SNPs) [14]. Among these SNPs, +869 T/C (also known as rs1000470, T29C, or Leu10Pro) and +915 G/C (also termed as rs1000471, G74C, or Arg25Pro) polymorphisms in the first exon of **TGFBI** have been the focus of extensive research and donor **TGFBI** +869 T/C polymorphism has been proven to be significantly associated with AR risk [15]. These two SNPs together result in nine potential inherited haplotypes, which could be categorized into three groups according to the in vitro production levels: high producer (HP) (T/T G/G and T/C G/G), intermediate producer (IP) (T/C G/C, T/T G/C, and C/C G/G) and low producer (LP) (C/C G/C, C/C C/C, T/T C/C and T/C C/C) [16,17]. Since the first study conducted by Pelletier et al to evaluate the haplotype association of **TGFBI** +869 T/C and +915 G/C polymorphisms with AR risk in kidney transplant recipients [18], numerous molecular epidemiological studies have been conducted in different solid organ transplants, including kidney transplants [19–26], liver transplants [9,27,28], and heart transplants [13,29]. However, the results of these studies were inconclusive.

In this meta-analysis, we integrated the data from all eligible studies to explore 1) the combined effects of recipient **TGFBI** +869 T/C and +915 G/C polymorphisms on AR risk after solid organ transplantation and 2) the potential influence of covariants such as ethnicity, transplantation types, and immunosuppressive protocols.

**Materials and Methods**

**Identification of eligible studies**

This meta-analysis was conducted and reported in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines (Checklist S1) [30]. To identify all eligible studies that investigated the haplotype association of **TGFBI** +869 T/C and +915 G/C polymorphisms with AR risk in solid organ transplantation, a comprehensive electronic search of PUBMED, EMBASE, China National Knowledge Infrastructure (CNKI), and Wanfang databases was performed until November 29, 2013. To search and include as many related studies as possible, we applied various combinations of the following medical subject headings and key words: transforming growth factor beta-1, TGFBI-1, or TGFBI; acute rejection, early allograft outcome, or graft rejection; transplantation or organ transplantation; polymorphisms or variants. Furthermore, the reference lists of reviews and retrieved articles were manually screened for additional studies. No restrictions were placed on language, and only published studies with full-text articles were included.

**Inclusion and exclusion criteria**

The studies identified from the above mentioned databases were screened by two independent authors (Yu-Zheng Ge and Ran Wu) according to the following prespecified inclusion criteria: 1) case-control design; 2) evaluating the correlation of **TGFBI** haplotypes (at position +869 and +915) with AR risk; and 3) providing sufficient data to calculate the odds ratio (OR) and its corresponding 95% confidence interval (CI). When several studies with overlapping data were eligible, those with smaller sample size or less reliability were excluded. In addition, studies without detailed information were excluded, after the efforts to extract data from the original paper or contact the corresponding authors failed.

**Data extraction**

Data of eligible studies were extracted by two reviewers (Yu-Zheng Ge and Tian-Ze Lu) independently and in duplicate according to the prespecified data-collection form. The following information was extracted: last name of first author, publication year, country of origin, ethnicity, transplantation type, immunosuppressive protocol, number of both ARs and non-ARs and phenotypic distribution in both groups. Different ethnic descents were categorized as Asian, Caucasian, African and Mixed (which included more than one ethnic descent). Transplantation types were characterized as renal, liver, and heart transplantation. Based on different calcineurin inhibitors (CNIs) within the immunosuppressive protocol, the studies were divided into two subgroups: Cyclosporine A (CsA) group and CsA/tacrolimus (FK506) group. Discrepancies occurring during the process of study inclusion and data extraction were resolved by discussion with a third reviewer (Wen-Cheng Li), and consensus on each item was achieved eventually.

**Statistical analysis**

Crude OR and its corresponding 95% CI were used to assess the strength of association between the haplotypes of +869 T/C and +915 G/C polymorphisms in **TGFBI** gene and AR risk. The HP haplotypes (T/T G/G and T/C G/G) were used as the baseline for calculation of ORs in three different comparisons (LP vs. HP, IP vs. HP and LP/IP vs. HP). Stratified analyses were also conducted based on ethnicity, transplantation types, and immunosuppressive protocols. The statistical significance of the pooled OR was assessed with the Z test, and P<0.05 was considered significant.

Chi-square based Q-test was performed to measure between-study heterogeneity, and the presence of heterogeneity was considered significant if P<0.10 [31]. When the heterogeneity was absent, the fixed-effect model (Mantel-Haenszel method) was used to pool the data from different studies [32]; otherwise, the random-effects model (DerSimonian and Laird method) was applied [33]. Sensitivity analyses were conducted to identify the effect of individual study on pooled results and to test the reliability of results by deleting a single study each time [34]. To determine the presence of publication bias, both Begg’s funnel plot and Egger’s linear regression test were conducted, and P<0.05 was considered significant [35,36].

All statistical analyses were performed with STATA software (version 12.0; Stata Corporation, College Station, Texas, USA) and Review Manager (version 5.0; Cochrane Collaboration, Oxford, UK).

**Results**

**Characteristics of eligible studies**

Fourteen eligible articles were identified according to the prespecified selection criteria, and the detailed screening process was shown in Figure 1. Among the 14 eligible studies, 9 were renal transplantation [18–26], 3 were liver transplantation [9,27,28], and 2 were heart transplantation [13,29]. As for ethnicity, 7 were studies of Caucasians [9,22,23,27,28,37], 3 studies were of Asians [19–21], and 4 studies of mixed ethnicity [13,18,26,29]. Regarding the immunosuppressive protocols, patients were uniformly prescribed with CsA in 5 studies [18–20,23,29] while in the remaining 9 studies were applied with either CsA or FK506 [9,13,21,22,24–28] (Table 1).

**Quantitative data synthesis**

A total of 14 studies including 565 AR and 1219 non-AR cases were identified to assess the haplotype association of **TGFBI** +869 T/C and +915 G/C polymorphisms with AR risk of solid organ transplantation. Overall, a significantly decreased risk was
detected in two comparisons (IP vs. HP: OR = 0.75, 95% CI, 0.58–0.96, P heterogeneity = 0.238, Figure 2; IP/LP vs. HP: OR = 0.77, 95% CI, 0.61–0.98, P heterogeneity = 0.144, Figure 3). Subgroup analyses based on ethnicity, transplant types, and immunosuppressive protocols were subsequently conducted, and the results demonstrated a remarkably decreased risk in heart transplant recipients (IP vs. HP: OR = 0.32, 95% CI, 0.14–0.73, P heterogeneity = 0.790, Figure 2; IP/LP vs. HP: OR = 0.41, 95% CI, 0.20–0.85, P heterogeneity = 0.320, Figure 3) and in patients uniformly administrated with CsA (IP vs. HP: OR = 0.57, 95% CI, 0.34–0.94, P heterogeneity = 0.491). Table 2 represents the strength of association between $\text{TGFB1}$ haplotypes (at position +869 and +915) and AR risk in transplant recipients.

**Heterogeneity test and sensitivity analysis**

No significant between-study heterogeneity was observed in this meta-analysis (Table 2). Sensitivity analysis was also performed to explore the potential influence of each individual study on the overall results by deleting one single study each time from the pooled analysis. NO substantial change was demonstrated in the overall studies, indicating that no individual study could affect the pooled OR significantly (data not shown).

**Publication bias**

To examine the publication bias of the currently available literature, both Begg’s funnel plot and Egger’s test were conducted. The shape of the funnel plots did not reveal any evidence of obvious asymmetry in all comparison models (Figures S1, S2, S3). Then, the Egger’s test was used to provide statistical evidence for funnel plot symmetry. The results also did not show any evidence of publication bias (Table S1).

**Discussion**

Organ transplantation has been recommended as the most optimal treatment choice for patients suffering end-stage disease. However, AR still remains a crucial determining factor which influences the short-term function and long-term outcome of both recipients and allografts [38–40]. To the best of our knowledge, this is the first meta-analysis focusing on the combined effects of $\text{TGFB1}$ +869 T/C and +915 G/C polymorphisms on AR risk. In the current study, we provide evidence that patients carried with $\text{TGFB1}$ HP haplotypes (T/T G/G and T/C G/G) are more likely to suffer from AR after solid organ transplantation (specifically heart transplantation), which could be utilized to identify patients...
Table 1. Characteristics and haplotypes distribution of eligible studies included in the meta-analysis.

| Author     | Year | Country | Ethnicity | Transplant types | CNIs          | AR/non-AR | AR cases | Non-AR | HP | IP | LP | HP | IP | LP |
|------------|------|---------|-----------|------------------|---------------|-----------|----------|--------|-----|-----|----|-----|-----|----|
| Pelletier  | 2000 | USA     | Mixed     | RTx              | CsA           | 25/46     | 7        | 17     | 1   | 15  | 28 | 3  |     |    |
| Tambur    | 2001 | USA     | Caucasian | LTx              | CsA/FK506     | 33/30     | 24       | 8      | 1   | 16  | 12 | 2  |     |    |
| Tian      | 2001 | China   | Asian     | RTx              | CsA           | 19/72     | 16       | 3      | 0   | 56  | 16 | 0  |     |    |
| Tian      | 2002 | China   | Asian     | RTx              | CsA           | 26/89     | 23       | 3      | 0   | 68  | 21 | 0  |     |    |
| Gu        | 2003 | China   | Asian     | RTx              | CsA/FK506     | 23/74     | 19       | 4      | 0   | 66  | 7  | 1  |     |    |
| Karasu    | 2004 | Turkey  | Caucasian | LTx              | CsA/FK506     | 26/17     | 19       | 7      | 0   | 11  | 6  | 0  |     |    |
| Gourley   | 2004 | USA     | Mixed     | HTx              | CsA           | 42/50     | 32       | 6      | 4   | 32  | 17 | 1  |     |    |
| Lachta    | 2005 | Czech   | Caucasian | RTx              | CsA/FK506     | 117/228   | 33       | 65     | 19  | 82  | 121| 25 |     |    |
| Di Filippo| 2006 | USA     | Mixed     | HTx              | CsA/FK506     | 39/72     | 36       | 3      | 0   | 54  | 16 | 2  |     |    |
| Gómez-Mateo| 2006 | Spain   | Caucasian | LTx              | CsA/FK506     | 42/108    | 32       | 9      | 1   | 74  | 27 | 7  |     |    |
| Canossi   | 2007 | Italy   | Caucasian | RTx              | CsA           | 25/61     | 19       | 5      | 1   | 37  | 21 | 3  |     |    |
| Kocierz   | 2011 | Poland  | Caucasian | RTx              | CsA/FK506     | 49/150    | 43       | 5      | 1   | 113 | 32 | 5  |     |    |
| Seyhun    | 2012 | Turkey  | Caucasian | RTx              | CsA/FK506     | 19/71     | 14       | 4      | 1   | 39  | 17 | 15 |     |    |
| Dhaouadi  | 2013 | Tunisia | Mixed     | RTx              | CsA/FK506     | 80/151    | 55       | 17     | 8   | 105 | 38 | 8  |     |    |

Abbreviations: RTx, renal transplantation; LTx, liver transplantation; HTx, heart transplantation; CNIs, calcineurin inhibitors; CsA, cyclosporine A; FK506, tacrolimus; AR, acute rejection; LP, low producer; IP, intermediate producer; HP, high producer.
doi:10.1371/journal.pone.0093938.t001
predisposed to AR and potentially benefiting from tailored immunosuppressive protocol.

After pooling the data from 14 eligible studies, we shown that patients with TGFB1 IP and/or LP haplotypes were less likely to suffer from AR than those with HP haplotypes (IP vs. HP: OR = 0.75, 95% CI, 0.58–0.96; IP/LP vs. HP: OR = 0.77, 95% CI, 0.61–0.98). Considering that ethnic background could influence the frequency of genotypes and haplotypes in some context, we conducted subgroup analysis based on ethnicities but failed to detect any significant association. Further stratified analysis by transplant types demonstrated a remarkably decreased AR risk for heart transplant recipients carrying TGFB1 IP and/or LP haplotypes, which was in agreement with the study conducted in a cohort of 111 pediatric cardiac transplant recipients [13]. With respect to various CNIs applied in suppressive protocols, CsA and FK506 have been proven to influence the serum level of TGF-β1 differentially [41,42]; thus, we intended to investigate the various impacts of different CNIs on the relationship between the TGFB1 haplotypes and AR risk. However, FK506 has never been administrated as a unique CNI in any included studies. Therefore, we divided the studies into two subgroups: CsA arm and CsA/FK506 arm, and then conducted a subgroup analysis. As a result, patients with TGFB1 IP haplotypes were less likely to be affected by AR in CsA arm (IP vs. HP: OR = 0.57, 95% CI, 0.34–0.94), which could be interpreted as a clue that the recipients with TGFB1 IP haplotypes can benefit from CsA after organ transplantation.

TGF-β1 is a pleiotropic and multifunctional cytokine with immunosuppressive and fibrogenic properties, which may play a central role in both the initiation and propagation of AR and chronic rejection (CR) [7,8]. The expression of TGF-β1 has been proven to be regulated by the two SNPs (+869 T/C and +915 G/C polymorphisms), whose combination could be divided into three groups (LP, IP, and HP), which could be interpreted as a clue that the recipients with TGFB1 IP haplotypes can benefit from CsA after organ transplantation.

**Figure 2. Forest plot for risk of acute rejection associated with TGFB1 haplotypes (IP vs. HP) stratified by transplant types.** For each study, the estimate of OR and its 95% CI is plotted with a box and a horizontal line. Filled diamond pooled OR and its 95% CI. doi:10.1371/journal.pone.0093938.g002
discrepancies, several questions have been raised: 1) The impact of various haplotypes of $TGFB1 +869$ T/C and $+915$ G/C polymorphisms on actual production levels of TGF-$\beta_1$. The effects of the nine potential haplotypes on TGF-$\beta_1$ expression levels have been previously studied in vitro and among patients without organ transplant [16,43,44]. However, no significant association between $TGFB1$ SNPs and TGF-$\beta_1$ plasma levels or intragraft mRNA levels was detected in a cohort of renal transplant recipients [45]. 2) The influence of various immunosuppressive protocols on the expression level of TGF-$\beta_1$. CsA and FK506 were found to influence the serum level of TGF-$\beta_1$ differentially [41,42,45], while the impact of other immunosuppressive regimens still remains elusive. 3) The potential effects of donor and/or donor-recipient pair $TGFB1$ haplotypes on AR risk. The current study is confined to recipient SNPs; however, in some context, donor polymorphisms may contribute much more to AR risk than recipient SNPs [15,46]. 4) The exact etiology of AR episodes and the biological functions of TGF-$\beta_1$ in the development of AR still remain unclear.

The current meta-analysis focused on the combined effects of $TGFB1 +869$ T/C and $+915$ G/C polymorphisms rather than one single SNP on AR risk [15], which could help to derive a precise estimation of the roles of $TGFB1$ SNPs in the development of AR episodes. However, several limitations should be considered when interpreting the results. First, considering the unavailability of other detailed information, we did not conduct stratified analysis based on some cofactors such as follow-up time, gender, age, panel reactive antibodies level, human leukocyte antigens mismatch and donor source, which may influence the results. Second, the limited number of AR cases and non-AR cases may lead to a relatively small power. Third, only published studies with sufficient data were included, thus, publication bias may have occurred even though results of both Begg’s test and Egger’s test did not detect it. Last but not least, the meta-analysis is retrospective due to the methodological limitations.

In summary, this meta-analysis suggested that recipient $TGFB1$ HP haplotypes of +869 T/C and +915 G/C polymorphisms (T/T G/G and T/C G/G) might be a possible genetic susceptibility
Table 2. Stratification analyses of combined effects of TGFβ1 +869 T/C and +915 G/C polymorphisms on acute rejection risk.

| Category                          | LP vs. HP | IP vs. HP | LP/IP vs. HP |
|-----------------------------------|-----------|-----------|--------------|
|                                   | N* | OR(95% CI) | Pb | Pc | N* | OR(95% CI) | Pb | Pc | N* | OR(95% CI) | Pb | Pc |
| Total                             | 11 | 1.10(0.71,1.71) | 0.665 | 0.373 | 14 | 0.75(0.58,0.96)d | 0.021d | 0.238 | 14 | 0.77(0.61,0.98)d | 0.030d | 0.144 |
| Ethnicity                         |     |           |     |     |     |           |     |     |     |           |     |     |
| Asian                             | 1  | 1.14(0.05,29.0) | 0.938 | —  | 3  | 0.76(0.36,1.60) | 0.466 | 0.242 | 3  | 0.74(0.35,1.55) | 0.423 | 0.303 |
| Caucasian                         | 6  | 0.93(0.54,1.61) | 0.807 | 0.165 | 7  | 0.80(0.58,1.10) | 0.174 | 0.251 | 7  | 0.78(0.58,1.06) | 0.112 | 0.094 |
| Mixed                             | 4  | 1.58(0.72,3.49) | 0.258 | 0.507 | 4  | 0.65(0.42,1.03) | 0.064 | 0.163 | 4  | 0.77(0.51,1.16) | 0.214 | 0.160 |
| Transplantation Types             |     |           |     |     |     |           |     |     |     |           |     |     |
| RTx                               | 7  | 1.23(0.75,2.01) | 0.406 | 0.401 | 9  | 0.88(0.66,1.17) | 0.377 | 0.290 | 9  | 0.91(0.69,1.19) | 0.473 | 0.154 |
| LTx                               | 2  | 0.33(0.07,1.69) | 0.185 | 0.996 | 3  | 0.64(0.35,1.16) | 0.142 | 0.737 | 3  | 0.59(0.33,1.06) | 0.076 | 0.774 |
| HTx                               | 2  | 1.50(0.34,6.57) | 0.594 | 0.180 | 2  | 0.32(0.14,0.73)d | 0.006d | 0.790 | 2  | 0.41(0.20,0.85)d | 0.017d | 0.320 |
| Immunosuppressive protocol        |     |           |     |     |     |           |     |     |     |           |     |     |
| CsA                               | 3  | 1.37(0.41,4.59) | 0.607 | 0.462 | 5  | 0.57(0.34,0.94)d | 0.027d | 0.491 | 5  | 0.62(0.38,1.01) | 0.055 | 0.694 |
| CsA/FK506                         | 8  | 1.07(0.66,1.71) | 0.793 | 0.229 | 9  | 0.82(0.62,1.09) | 0.169 | 0.194 | 9  | 0.83(0.64,1.08) | 0.162 | 0.059 |

Abbreviations: RTx, renal transplantation; LTx, liver transplantation; HTx, heart transplantation; CsA, cyclosporine A; FK506, tacrolimus; LP, low producer; IP, intermediate producer; HP, high producer.

*Number of eligible studies;
*P value of Z-test for significance of OR;
*P value of Q-test for heterogeneity test;
*Statistically significant results (in bold).
doi:10.1371/journal.pone.0093938.t002
locus for AR after solid organ transplantation, which could be utilized to identify patients predisposed to AR and potentially benefiting from personalized immunosuppressive protocol. In addition, monitoring TGFβ1 could help manage CR to some extent, as TGFβ1 triggers fibrogenesis linked to chronic rejection (CR). Further well-designed and unbiased studies with larger sample size, diverse ethnicities, donor-recipient pairing and various applications of CNIs should be conducted to verify our findings. Furthermore, functional studies of TGFβ1 gene polymorphism are warranted to understand the underlying mechanisms.

Supporting Information

Figure S1 Begg’s funnel plot for publication bias test (LP vs. HP for TGFβ1 haplotypes).

Figure S2 Begg’s funnel plot for publication bias test (IP vs. HP for TGFβ1 haplotypes).

References

1. Li MO, Flavel RA (2008) TGF-beta: a master of all T cell trades. Cell 134: 392–404.
2. Blobi GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350–1358.
3. Edgley AJ, Krum H, Kelly DJ (2012) Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc Ther 30: e10–40.
4. Massaguer J (2008) TGFβ1 in Cancer. Cell 134: 215–230.
5. Hussein YM, Mohamed RH, El-Shahawy EE, Alzahrani SS (2014) Interaction between TGF-betα (869C/T) polymorphism and biochemical risk factor for prediction of disease progression in rheumatoid arthritis. Gene 536: 393–397.
6. Gagliardo R, Chanez P, Gjomarkaj M, La Grutta S, Bonanno A, et al. (2013) The role of transforming growth factor-beta1 in airway inflammation of childhood asthma. Int J Immunopharmacol Pharmacol 26: 725–738.
7. Hutchinson IV (1999) The role of transforming growth factor-beta in transplant rejection. Transplant Proc 31: 98–138.
8. Morris-Stiff G (2005) TGFβ1 and the development of chronic graft nephropathy: relative roles of gene, mRNA and protein. Ann R Coll Surg Engl 87: 326–330.
9. Tambur AR, Ortegel JW, Ben-Ari Z, Shabtai E, Klein T, et al. (2001) Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 71: 1473–1480.
10. Pribylova-Hrivova P, Kotski I, Lodererova A, Valicky O, Virko S, et al. (2006) TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int 69: 1872–1879.
11. Benza RL, Coffey CS, Pekaré DM, Barchue JP, Tallaj JA, et al. (2009) Transforming growth factor-beta polymorphisms and cardiac allograft rejection. J Heart Lung Transplant 28: 1057–1062.
12. Hoffmann S, Park J, Jacobson LM, Muehrer RJ, Lorentzen D, et al. (2004) Genomic influences on graft and cardiac allograft nephropathy. Kidney Int 66: 1606–1613.
13. Di Filippo S, Zeevi A, McLeod K, Bastian O, Webber SA (2006) Impact of TGFbeta1 gene polymorphisms on acute and chronic rejection in pediatric heart transplant allografts. Transplantation 81: 934–939.
14. Shah R, Rahaman B, Hurley CK, Posch PE (2006) Allelic diversity in the TGFβ1 regulatory region: characterization of novel functional single nucleotide polymorphisms. Humin Geneit 119: 61–74.
15. Ge VZ, Yu P, Jia RP, Wu R, Ding AX, et al. (2014) Association between transforming growth factor beta-1 +869T/C polymorphism and acute rejection of solid organ allograft: A meta-analysis and systematic review. Transpl Immunol http://dx.doi.org/10.1016/j.trim.2014.01.001.
16. Asaad MR, El-Gamal A, Haiduton P, Turner DM, Simonet PJ, et al. (1998) Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66: 1014–1020.
17. Perrey C, Pravica V, Simonet PJ, Hutchinson IV (1998) Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol 6: 193–197.
18. Pelletier R, Pravica V, Perrey C, Xia D, Ferguson RM, et al. (2000) Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 70: 674–680.
19. Tian Y, Ma W, Zhang Y (2001) Influence of cytokine gene polymorphism on renal transplantation. Zhonghua Yi Xue Za Zhi 81: 719–721.
20. Tian Y, Ma W, Zhang Y (2002) Influence of cytokine gene polymorphism on renal transplantation. Zhonghua Wai Ke Za Zhi 40: 236–250.
21. Gu XW, Zhao M, Li LY, Li J, Ji J (2003) Cytokine gene polymorphism in sensitized kidney transplant recipients and its association with acute rejection episodes. Di Yi Jun Yi Da Xue Xue Bao 23: 1211–1213.
22. Lachaj J, Hrivova P, Kotski I, Brabova I, Bartosova K, et al. (2009) Effect of cytokines and chemokines (TGF-beta, TNF-alpha, IL-6, IL-10, MCP-1, RANTES) gene polymorphisms in kidney recipients on posttransplantation outcome: influence of donor-recipient match. Transplant Proc 37: 764–766.
23. Canossa A, Piazza A, Poggi E, Ozzella G, Di Rocco M, et al. (2007) Renal allograft immune response is influenced by patient and donor cytokine genotypes. Transplant Proc 39: 1805–1812.
24. Kocierz M, Sierkiewicz U, Kolosko A, Karkoszka H, Chudek J, et al. (2011) -174TG/CC interlink-6 gene polymorphism and the risk of transplanted kidney failure or graft loss during a 5-year follow-up period. Tissue Antigens 77: 203–290.
25. Seyhun Y, Mytilineos J, Turkmen A, Oguz F, Kekic C, et al. (2012) Influence of cytokine gene polymorphisms on graft rejection in Turkish patients with renal transplants from living related donors. Transplant Proc 44: 1676–1678.
26. Dhauoudi T, Sfar I, Bardi R, Jendoubi-Aved S, Abdallah TB, et al. (2013) Cytokine gene polymorphisms in kidney transplantation. Transplant Proc 45: 2152–2157.
27. Karazu Z, Ulokaya S, Ayanoogu HO, Basturk B, Ulokaya E, et al. (2004) Cytokine gene polymorphism and early graft rejection in liver transplant recipients. Transplant Proc 36: 2791–2795.
28. Gomez-Mateo J, Marin L, Lopez-Alvarez MR, Moya-Quiles MR, Miram M, et al. (2006) TGF-beta1 gene polymorphism in liver graft recipients. Transpl Immunol 17: 55–57.
29. Gourley IS, Denofrio D, Rand W, Desai S, Loh E, et al. (2004) The effect of recipient cytokine gene polymorphism on cardiac transplantation outcome. Hum Immunol 65: 248–254.
30. Moreh D, Liberati A, Testai J, Altman DG (2008) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 537–560.
32. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
33. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
34. Thakkinstian A, McElhuff P, D’Este C, Duffy D, Attia J (2005) A meta-analysis for meta-analysis of molecular association studies. Stat Med 24: 1291–1306.
35. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.
36. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
37. Seyhun Y, Mytilineos J, Turkmen A, Oguz F, Kekic C, et al. (2012) Influence of cytokine gene polymorphisms on graft rejection in Turkish patients with renal transplants from living related donors. Transplant Proc 44: 1241–1249.
38. Opelz G, Dohler B (2008) Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 85: 661–666.
39. Schilki J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, et al. (2012) The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant 31: 1052–1064.

Figure S3 Begg’s funnel plot for publication bias test (LP/IP vs. HP for TGFβ1 haplotypes).

(TIF)

Checklist S1 PRISMA checklist.

(DOC)

Table S1 Statistical analyses of publication bias for TGFβ1 haplotypes at +869 T/C and +915 G/C polymorphisms.

(DOC)

Author Contributions

Conceived and designed the experiments: YZG RPJ. Performed the experiments: YZG RW TZL MHL XFG XMX BXZ LPL SJT QS WCL JGZ. Analyzed the data: YZG RW TZL WCL JGZ. Contributed reagents/materials/analysis tools: YZG MHL XFG BXZ LPL. Wrote the paper: YZG RW LPL. Proofread and revised the paper: RPJ.
40. Thurairajah PH, Carbone M, Bridgestock H, Thomas P, Hebbar S, et al. (2013) Late acute liver allograft rejection; a study of its natural history and graft survival in the current era. Transplantation 95: 955–959.

41. Dai J, Michineau S, Franck G, Desgranges P, Becquemin JP, et al. (2011) Long term stabilization of expanding aortic aneurysms by a short course of cycloporine A through transforming growth factor-beta induction. PLoS One 6: e28903.

42. Pakosz K, Zakliczynski M, Krol W, Pyka L, Zakliczynska H, et al. (2012) Association of transforming growth factor beta1 (TGF- beta1) with gingival hyperplasia in heart transplant patients undergoing cycloporine-A treatment. Ann Transplant 17: 45–52.

43. Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, et al. (1998) Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 13: 1569–1576.

44. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, et al. (2000) Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 97: 3479–3484.

45. Hueso M, Navarro E, Moroso F, Beltran-Sastre V, Ventura F, et al. (2006) Relationship between subclinical rejection and genotype, renal messenger RNA, and plasma protein transforming growth factor-beta1 levels. Transplantation 81: 1463–1466.

46. Lv R, Hu X, Bai Y, Long H, Xu L, et al. (2012) Association between IL-6 -174G/C polymorphism and acute rejection of renal allograft: evidence from a meta-analysis. Transpl Immunol 26: 11–18.